- Home
- RGS vs IMA Comparison
RGS vs IMA Comparison
Compare RGS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGS | IMA |
|---|---|---|
| Founded | 1922 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 66.3M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | RGS | IMA |
|---|---|---|
| Price | $26.82 | $5.75 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 4.1K | ★ 13.5K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.24 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $210,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.26 | ★ N/A |
| Revenue Growth | ★ 3.52 | N/A |
| 52 Week Low | $18.23 | $3.94 |
| 52 Week High | $31.50 | $17.50 |
Technical Indicators
Market Signals| Indicator | RGS | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 53.05 |
| Support Level | $26.06 | $5.70 |
| Resistance Level | $28.51 | $6.06 |
| Average True Range (ATR) | 0.74 | 0.29 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 30.28 | 57.75 |
Price Performance
Historical ComparisonAbout RGS Regis Corporation
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.